ClinicalTrials.Veeva

Menu
B

Beverly Hills Cancer Center | Beverly Hills, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Nivolumab
Palbociclib
Letrozole
Elranatamab
Sitravatinib
LY2835219
Cisplatin
Exemestane
Pembrolizumab
Enzalutamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 65 total trials

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20)

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elran...

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: Maplirpacept

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Active, not recruiting
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with place...

Active, not recruiting
Breast Cancer
Drug: Placebo
Drug: Fulvestrant

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizu...

Active, not recruiting
Endometrial Cancer
Solid Tumor, Unspecified, Adult
Drug: Fruquintinib
Drug: Tislelizumab

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in part...

Active, not recruiting
Endometrial Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Everolimus

This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small ce...

Enrolling
Non-small Cell Lung Cancer
Drug: MK-1084
Other: Placebo

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicul...

Enrolling
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or meta...

Active, not recruiting
Nonsmall Cell Lung Cancer
Drug: HS-10296

The purpose of this study is to learn about the:* safety (the effect of the study medicine on the participant's body),* effects of the study medicine...

Enrolling
Colorectal Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Biological: sasanlimab
Other: SOC (anti-PD-1 + platinum -based chemo)
Locations recently updated

This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of...

Enrolling
Neoplasms
Drug: Ezabenlimab
Drug: BI 765179

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Abemaciclib

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the t...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/ref...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer ther...

Enrolling
Multiple Myeloma
Drug: Elranatamab + lenalidomide + dexamethasone
Drug: Elranatamab + Nirogacestat

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), opt...

Enrolling
Advanced Non-Small Cell Squamous Lung Cancer
Epidermal Growth Factor Receptor C797S
Drug: BDTX-1535 monotherapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: Cetuximab
Drug: Afatinib

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanc...

Active, not recruiting
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Drug: Sitravatinib
Drug: Docetaxel

This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants w...

Enrolling
Metastatic Breast Cancer
Drug: Letrozole
Drug: Ribociclib

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at...

Enrolling
Locally Advanced Breast Cancer
Metastatic Triple Negative Breast Cancers
Drug: BNT327 Equivalent Q3W Dose
Drug: BNT327 Dose Level 1 (DL2)

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with...

Enrolling
Carcinoma, Non-Small-Cell Lung Cancer
Biological: KB-GDT-01

Trial sponsors

Pfizer logo
Lilly logo
G
Mirati Therapeutics logo
Novartis logo
Boehringer Ingelheim logo
Genentech logo
Genmab logo
Gilead Sciences logo
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems